EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration

Alyson Mathis iD, Matthew Lane, Jennifer Meyer Reid

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900241292692 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Alyson Mathis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Sulfonylurea Compounds. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to their mechanism of action, sodium-glucose cotransporter-2 inhibitors (SGLT2is) carry a presumed increased risk of urinary tract infection (UTI) which is reflected in current prescribing data. As SGLT2i prescribing trends increase, some retrospective studies confirm an increased risk of UTI while conflicting studies find no increased risk of UTI associated with this therapy.

Objectives

This study aims to compare the odds of developing a UTI in male Veterans with type 2 diabetes mellitus (T2DM) on metformin taking a SGLT2i vs a sulfonylurea (SU) within the Veterans Health Administration (VHA).

Methods

This retrospective cohort study identified male Veterans with T2DM on metformin with a new fill of SGLT2i or SU between January 1, 2020 to December 31, 2022. Patients were then assessed for UTI diagnosis. An adjusted odds ratio (AOR) was calculated.

Results

The SGLT2i cohort had 5.2% of patients diagnosed with outpatient UTI and 1.6% of patients diagnosed with inpatient UTI. The SU cohort had 5.3% of patients diagnosed with outpatient UTI and 1.3% of patients diagnosed with inpatient UTI. A logistic regression analysis resulted in a decreased odds of diagnosis of outpatient UTI in the SGLT2i cohort vs the SU cohort ([AOR] = 0.91, 95% CI [0.86 – 0.96], P -value = < 0.001), and no difference in the diagnosis of inpatient UTI ([AOR] = 1.06, 95% CI [0.96 – 1.18], P -value = 0.234).

Conclusion

This retrospective study of national VHA data adds to growing literature which finds no excessive risk of UTI associated with SGLT2i therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Sulfonylurea CompoundsHypoglycemic AgentsHumansMaleRetrospective StudiesUnited StatesMiddle AgedAgedUnited States Department of Veterans AffairsVeteransCohort StudiesMetforminRisk Factors

Stichwörter der Autor:innen

SGLT2itype 2 diabetes mellitusurinary tract infection

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsHypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA.

ORCID-Profile: Alyson Mathis

Zitieren

APA

Mathis, A., Lane, M., & Reid, J. M. (2025). Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241292692

Vancouver

Mathis A, Lane M, Reid JM. Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241292692

BibTeX
@article{Mathis2025,
  author = {Mathis, Alyson and Lane, Matthew and Reid, Jennifer Meyer},
  title = {Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900241292692}
}
Kostenlos starten →